Vincenzo De Giorgi1,2, Alessia Gori3, Imma Savarese4, Antonietta D'Errico4, Federica Scarfì4, Federica Papi4, Vincenza Maio5, Piero Covarelli6, Daniela Massi5, Sara Gandini7. 1. Department of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy. vincenzo.degiorgi@unifi.it. 2. Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy. vincenzo.degiorgi@unifi.it. 3. Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy. 4. Department of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy. 5. Department of Human Pathology and Oncology, University of Florence, Florence, Italy. 6. Department of Dermatology, University of Perugia, Perugia, Italy. 7. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
Abstract
BACKGROUND: Currently, the association between body mass index (BMI) and hormone therapies and Cutaneous Melanoma (CM) development is strongly debated. This study was carried out to assess the association between BMI, hormone therapies, and CM risk. METHODS: The present study is a hospital-based case-control study with 605 consecutive CM patients and 592 controls treated for non-neoplastic conditions at the Department of Dermatology in Florence. The associations of melanoma risk with BMI and hormone therapies were assessed performing unconditional logistic regression to estimate odds ratios (OR) and their 95% confidence intervals, adjusting for potential confounders. RESULTS: We found a significant interaction of BMI with age (P < 0.0001): being overweight significantly increased CM risk among individuals less than 50 years old (OR = 1.85 with 95% CI 1.14-2.94), whereas the association was not significant for individuals over 50 years old (OR = 1.15 with 95% CI 0.77-1.71). For oestrogen therapy, women taking oral contraceptives (OCs)/hormone replacement therapy (HRT) showed a lower CM risk than men (OR = 0.63, 95% CI 0.44-0.89), with risk estimates significantly lower (P < 0.0001) than in non OCs/HRT users, which had an increased risk compared to men (OR = 1.81, 95% CI 1.29-2.53). CONCLUSIONS: Being overweight was significantly associated with CM risk, and this relationship was highly age-conditioned; the second finding was the protective effect of oestrogen therapies for women. Both findings may have a significant impact on melanoma prevention, as the prevalence of obesity and hormone therapy use is increasing worldwide.
BACKGROUND: Currently, the association between body mass index (BMI) and hormone therapies and Cutaneous Melanoma (CM) development is strongly debated. This study was carried out to assess the association between BMI, hormone therapies, and CM risk. METHODS: The present study is a hospital-based case-control study with 605 consecutive CM patients and 592 controls treated for non-neoplastic conditions at the Department of Dermatology in Florence. The associations of melanoma risk with BMI and hormone therapies were assessed performing unconditional logistic regression to estimate odds ratios (OR) and their 95% confidence intervals, adjusting for potential confounders. RESULTS: We found a significant interaction of BMI with age (P < 0.0001): being overweight significantly increased CM risk among individuals less than 50 years old (OR = 1.85 with 95% CI 1.14-2.94), whereas the association was not significant for individuals over 50 years old (OR = 1.15 with 95% CI 0.77-1.71). For oestrogen therapy, women taking oral contraceptives (OCs)/hormone replacement therapy (HRT) showed a lower CM risk than men (OR = 0.63, 95% CI 0.44-0.89), with risk estimates significantly lower (P < 0.0001) than in non OCs/HRT users, which had an increased risk compared to men (OR = 1.81, 95% CI 1.29-2.53). CONCLUSIONS: Being overweight was significantly associated with CM risk, and this relationship was highly age-conditioned; the second finding was the protective effect of oestrogen therapies for women. Both findings may have a significant impact on melanoma prevention, as the prevalence of obesity and hormone therapy use is increasing worldwide.
Entities:
Keywords:
Age; Body mass index; Cutaneous melanoma; Hormone therapies; Overweight status
Authors: Anne W Taylor; Eleonora Dal Grande; Tiffany K Gill; Catherine R Chittleborough; David H Wilson; Robert J Adams; Janet F Grant; Patrick Phillips; Sarah Appleton; Richard E Ruffin Journal: Aust N Z J Public Health Date: 2006-06 Impact factor: 2.939
Authors: Elizabeth L Brandon; Jian-Wei Gu; Lauren Cantwell; Zhi He; Gray Wallace; John E Hall Journal: Cancer Biol Ther Date: 2009-10 Impact factor: 4.742
Authors: M R Karagas; T A Stukel; J Dykes; J Miglionico; M A Greene; M Carey; B Armstrong; J M Elwood; R P Gallagher; A Green; E A Holly; C S Kirkpatrick; T Mack; A Østerlind; S Rosso; A J Swerdlow Journal: Br J Cancer Date: 2002-04-08 Impact factor: 7.640
Authors: Leon Alexander Mclaren Berge; Bettina Kulle Andreassen; Jo S Stenehjem; Trond Heir; Kari Furu; Asta Juzeniene; Ingrid Roscher; Inger Kristin Larsen; Adele C Green; Marit B Veierød; Trude E Robsahm Journal: Clin Epidemiol Date: 2020-02-21 Impact factor: 4.790